Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
EPS Growth Under PressureDecelerating
Percentile Rank44
5Y CAGR-36.7%
Year-over-Year Change
Year-over-year earnings per share growth rate
5Y CAGR
-36.7%/yr
Long-term compound
Percentile
P44
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.53% |
| Q3 2025 | 52.00% |
| Q2 2025 | 31.58% |
| Q1 2025 | 200.00% |
| Q4 2024 | 51.28% |
| Q3 2024 | 47.30% |
| Q2 2024 | -469.23% |
| Q1 2024 | -131.71% |
| Q4 2023 | 474.23% |
| Q3 2023 | 109.27% |
| Q2 2023 | -290.25% |
| Q1 2023 | 82.06% |
| Q4 2022 | -2300.00% |
| Q3 2022 | 123.81% |
| Q2 2022 | 75.58% |
| Q1 2022 | -514.29% |
| Q4 2021 | -153.85% |
| Q3 2021 | 36.84% |
| Q2 2021 | 171.43% |
| Q1 2021 | -50.00% |
| Q4 2020 | 103.53% |
| Q3 2020 | -3153.85% |
| Q2 2020 | 116.67% |
| Q1 2020 | -40.00% |
| Q4 2019 | 134.48% |
| Q3 2019 | 53.97% |
| Q2 2019 | -530.00% |
| Q1 2019 | 96.43% |
| Q4 2018 | -1233.33% |
| Q3 2018 | -16.67% |
| Q2 2018 | -117.31% |
| Q1 2018 | 109.17% |
| Q4 2017 | -2280.77% |
| Q3 2017 | 108.84% |
| Q2 2017 | -1131.58% |
| Q1 2017 | 159.37% |
| Q4 2016 | -374.29% |
| Q3 2016 | 25.00% |
| Q2 2016 | -54.84% |
| Q1 2016 | 10.71% |